Ever Supreme Bio Technology Co. Ltd
Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells in Taiwan. It operates in two segments: Cell Preparation Business and Other Operating Business segments. The company's products include umbilical cord mesenchymal stem cells (UMC01), a drug candidate in Phase I clinical trials for the… Read more
Market Cap & Net Worth: Ever Supreme Bio Technology Co. Ltd (6712)
Ever Supreme Bio Technology Co. Ltd (TWO:6712) has a market capitalization of $371.98 Million (NT$12.31 Billion) as of March 19, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #13424 globally and #430 in its home market, demonstrating a -3.44% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ever Supreme Bio Technology Co. Ltd's stock price NT$140.50 by its total outstanding shares 87597000 (87.60 Million).
Ever Supreme Bio Technology Co. Ltd Market Cap History: 2018 to 2026
Ever Supreme Bio Technology Co. Ltd's market capitalization history from 2018 to 2026. Data shows growth from $187.03 Million to $375.95 Million (11.32% CAGR).
Ever Supreme Bio Technology Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ever Supreme Bio Technology Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.60x
Ever Supreme Bio Technology Co. Ltd's market cap is 0.60 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.84x
Ever Supreme Bio Technology Co. Ltd's market cap is 0.84 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $324.99 Million | $70.60 Million | -$106.83 Million | 4.60x | N/A |
| 2021 | $389.81 Million | $438.84 Million | $369.60 Million | 0.89x | 1.05x |
| 2022 | $461.86 Million | $627.51 Million | $200.71 Million | 0.74x | 2.30x |
| 2023 | $455.17 Million | $758.39 Million | $539.40 Million | 0.60x | 0.84x |
Competitor Companies of 6712 by Market Capitalization
Companies near Ever Supreme Bio Technology Co. Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to Ever Supreme Bio Technology Co. Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Ever Supreme Bio Technology Co. Ltd Historical Marketcap From 2018 to 2026
Between 2018 and today, Ever Supreme Bio Technology Co. Ltd's market cap moved from $187.03 Million to $ 375.95 Million, with a yearly change of 11.32%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$375.95 Million | -13.41% |
| 2025 | NT$434.20 Million | -6.55% |
| 2024 | NT$464.64 Million | +2.08% |
| 2023 | NT$455.17 Million | -1.45% |
| 2022 | NT$461.86 Million | +18.48% |
| 2021 | NT$389.81 Million | +19.94% |
| 2020 | NT$324.99 Million | +8.68% |
| 2019 | NT$299.05 Million | +59.89% |
| 2018 | NT$187.03 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Ever Supreme Bio Technology Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $371.98 Million USD |
| MoneyControl | $371.98 Million USD |
| MarketWatch | $371.98 Million USD |
| marketcap.company | $371.98 Million USD |
| Reuters | $371.98 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.